World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
43148
World Ranking
15855
National Ranking
619

Overview

Mario Mandalà is affiliated with the European Institute of Oncology in Italy and has a significant body of work primarily concentrated in Medicine and Biochemistry, Genetics and Molecular Biology. Their research covers various subfields including Oncology, Molecular Biology, Immunology, Pulmonary and Respiratory Medicine, and Organic Chemistry.

The researcher has contributed extensively to topics such as:

  • Melanoma and MAPK Pathways
  • Cutaneous Melanoma Detection and Management
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Colorectal Cancer Treatments and Studies
  • Click Chemistry and Applications

Notable recent papers authored or co-authored by Mandalà include:

  • Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial (2020) published in The Lancet Oncology
  • Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo (2020) published in JAMA Oncology
  • Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma (2020) published in New England Journal of Medicine
  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial (2021) published in The Lancet Oncology
  • Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline (2023) published in Annals of Oncology

Frequent collaborators in their work include:

  • Paolo A. Ascierto
  • Caroline Robert
  • Dirk Schadendorf
  • Reinhard Dummer
  • Ana Arance

Mario Mandalà's research appears regularly in several publication venues, including:

  • Annals of Oncology
  • European Journal of Cancer
  • Journal of Clinical Oncology
  • The Lancet Oncology
  • Journal for ImmunoTherapy of Cancer

This body of work reflects a focus on cancer treatment and immunotherapy, with detailed investigations into melanoma management and immune-related cancer therapies. Their affiliation with a major oncology institute complements this specialized research area, integrating clinical and molecular approaches to cancer study.

Best Publications

  • Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

    James Larkin;Paolo A. Ascierto;Brigitte Dréno;Victoria Atkinson

  • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

    Charles S. Fuchs;Toshihiko Doi;Raymond W. Jang;Raymond W. Jang;Kei Muro

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

  • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

    G. V. Long;A. Hauschild;M. Santinami;V. Atkinson

  • Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    R. Labianca;B. Nordlinger;G. D. Beretta;S. Mosconi

  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo

  • Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

    Caroline Robert;Jean J Grob;Daniil Stroyakovskiy;Boguslawa Karaszewska

  • Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

    Paolo A Ascierto;Grant A McArthur;Grant A McArthur;Brigitte Dréno;Victoria Atkinson

  • Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

    Reinhard Dummer;Paolo A Ascierto;Helen J Gogas;Ana Arance

  • Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

    Giancarlo Agnelli;Gualberto Gussoni;Carlo Bianchini;Melina Verso

  • International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

    D Farge;P Debourdeau;M Beckers;C Baglin

  • Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

    G. V. Long;K. T. Flaherty;D. Stroyakovskiy;H. Gogas

  • Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines.

    M. Mandalà;A. Falanga;F. Roila

  • Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

    Reinhard Dummer;Paolo A Ascierto;Helen J Gogas;Ana Arance

  • 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

    Dominique Farge;Dominique Farge;Corinne Frere;Jean M Connors;Cihan Ay

  • Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

    Reinhard Dummer;Dirk Schadendorf;Paolo A Ascierto;Ana Arance

  • Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.

    Paolo A. Ascierto;Michele Del Vecchio;Mario Mandalá;Helen Gogas

Frequent Co-Authors

Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Georgina V. Long
Georgina V. Long University of Sydney
Caroline Robert
Caroline Robert University of Paris-Saclay
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Sandro Barni
Sandro Barni Mario Negri Institute for Pharmacological Research
Reinhard Dummer
Reinhard Dummer University of Zurich
Claus Garbe
Claus Garbe University of Tübingen
Vanna Chiarion-Sileni
Vanna Chiarion-Sileni European Institute of Oncology
Michele Maio
Michele Maio University of Siena

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in Medicine doesn’t always mean following a traditional MD route. There are a variety of online dnp programs without dissertation that allow working nurses to advance their credentials with more flexibility and less intensive research requirements. These programs are ideal for those looking to move into leadership, advanced clinical roles, or academia while balancing work and personal commitments.

For career changers or those eager to enter the healthcare workforce quickly, an accelerated lpn program provides a fast-track pathway into practical nursing. These online offerings are structured to deliver essential skills in a reduced timeframe, helping students secure stable, in-demand jobs faster.

Specializations are another way to boost your opportunities. With the rise of mental health awareness, online pmhnp programs (Psychiatric Mental Health Nurse Practitioner) enable nurses to focus on advanced mental health practice.

If you’re interested in leadership or the business side of healthcare, earning a healthcare administration degree online can open doors to management and executive roles across hospitals and clinics.

Best Scientists Citing Mario Mandalà

Trending Scientists

Recently Published Articles